32,270 Shares in Exelixis, Inc. $EXEL Acquired by Lifestyle Asset Management Inc.

Key Points

• Lifestyle Asset Management Inc. acquired 32,270 shares of Exelixis, Inc. valued at approximately $1.42 million, according to its Form 13F filing.
• Exelixis reported an earnings per share (EPS) of $0.75 for the most recent quarter, exceeding analysts' expectations of $0.63, but its revenue of $568.26 million fell short of the forecast.
• The stock has received mixed ratings from analysts, with thirteen giving a Buy rating, while the average price target stands at $44.06.

Lifestyle Asset Management Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 32,270 shares of the biotechnology company's stock, valued at approximately $1,422,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nuveen LLC bought a new stake in Exelixis in the 1st quarter valued at about $123,310,000. AQR Capital Management LLC grew its holdings in shares of Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company's stock valued at $250,869,000 after acquiring an additional 2,926,884 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock valued at $205,725,000 after acquiring an additional 1,596,948 shares in the last quarter. Jupiter Asset Management Ltd. grew its holdings in shares of Exelixis by 233.4% in the first quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company's stock valued at $51,698,000 after acquiring an additional 980,319 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in Exelixis during the fourth quarter valued at $30,321,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 0.9%

Exelixis stock traded down $0.35 during trading hours on Friday, hitting $40.10. 7,751,406 shares of the stock traded hands, compared to its average volume of 3,009,526. The firm's 50-day moving average price is $39.62 and its two-hundred day moving average price is $39.67. The company has a market cap of $10.80 billion, a PE ratio of 19.28, a PEG ratio of 0.83 and a beta of 0.32. Exelixis, Inc. has a one year low of $25.17 and a one year high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business's revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on EXEL shares. William Blair reissued an "outperform" rating on shares of Exelixis in a report on Tuesday, July 29th. The Goldman Sachs Group began coverage on Exelixis in a report on Wednesday. They set a "buy" rating and a $47.00 price objective on the stock. Morgan Stanley lifted their target price on Exelixis from $46.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday. Stifel Nicolaus increased their price target on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a report on Tuesday, July 29th. Finally, Truist Financial lowered their price objective on Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.